This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years
This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years
Grifols is a Spanish global pharmaceutical company specialising in the supply of blood plasma products.
Grifols, listed as a big pharma and big biotech company, has announced 4 M&A deals since 2005, with the lead deals being the acquisitions of Tacleris Pharmaceuticals.
Grifols, a global healthcare company, listed as big biotech and big pharma company aims to improve health and well-being of the people.
Grifols, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years
It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50.
By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.
STADA is a major global pharmaceutical company offering generics and OTC products.
Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc’s over-the-counter products unit in a deal that could boost earnings at both companies.
Swiss drugmaker Novartis can spend $4-6 billion per year on m&a to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.
Sorry, your search returned no results.
Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging
Grifols Diagnostic Division acquires Novartis transfusion diagnostics unit for $1.68 billion.
Grifols, a big pharma company, has entered pharma deals with Aradigm for licensing and options relating to Pulmaquin, Lipoquin and AERx.
Grifols, a big pharma company, has entered into a $41.4 million equity purchase financing deal with Aradigm.
Grifols and Talecris Biotherapeutics Holdings Corporation have signed a “Consent Agreement” with the Staff of the Bureau of Competition of the US Federal Trade Commission (FTC)
Spain’s Grifols has struck a $3.4 billion deal to buy Talecris Biotherapeutics, finally delivering a premium return for the investment groups that backed the Research Triangle Park, NC-based biotech. Read the Grifols / Talecris story at Reuters